RepliCel to Present Clinical Trial Update at Stem Cell Meeting on the Mesa Partnering Forum in California

VANCOUVER, BC – October 2, 2014 – RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), clinical stage regenerative medicine company focused on the development of autologous cell therapies will be presenting at the Stem Cell Meeting on the Mesa Partnering Forum on Tuesday, October 7, 2014 at 11:45 a.m. local time in La Jolla Ballroom 2 at the Estancia La Jolla Hotel.

The presentation by Mr. David Hall, CEO, will include an update on RepliCel’s pending clinical trials for chronic Achilles tendinosis (RCT-A-01) and sun-damaged and aging skin (RCS-01) as well as its program for pattern hair loss (RCH-01). It will be webcast and posted on the conference website at, on RepliCel’s website at and on the Alliance for Regenerative Medicine website, after the event, at bringing tremendous exposure to the company.

“The Stem Cell meeting does an excellent job of bring together leading researchers, clinical experts, senior executives, health care investors and top decision-makers in the regenerative medicine industry. With nearly 800 attendees from around the globe, it is a great environment for discussions around partnerships, collaborations and investment,” commented David Hall, CEO of RepliCel.

Please visit for full information on the conference including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only.

About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function. The company’s RCT-01, RCS-01 and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aging skin, and pattern baldness. Shiseido Company, Limited has an exclusive license for RCH-01 in certain Asian countries including Japan, China and South Korea. All product candidates are based on RepliCel’s innovative technology utilizing cell populations isolated from a patient’s own healthy hair follicles. The company is also developing a propriety injection device optimized for the administration of its products and licensable for use with other dermatology applications. The company’s product pipeline is comprised of multiple clinical trials all anticipated to launch in late 2014 in addition to Shiseido’s own clinical trial of RCH-01 and the device in late prototype development. Visit for additional information.

For more information please contact:

Tammey George, Director of Communications
Telephone: 604-248-8696

Christina Cameron, Investor Relations

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.